|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:L01EM01
|
|
gptkbp:brand
|
gptkb:Zydelig
|
|
gptkbp:CASNumber
|
870281-82-6
|
|
gptkbp:chemicalFormula
|
C22H18FN7O
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:developer
|
gptkb:Gilead_Sciences
|
|
gptkbp:eliminationHalfLife
|
8.2 hours
|
|
gptkbp:hasSMILES
|
C1=CC(=CC=C1C2=NC(=NC(=N2)N3CCN(CC3)C4=NC=C(C=C4)F)N)C(=O)N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
idelalisib
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
PI3K delta inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP3A
|
|
gptkbp:molecularWeight
|
415.42 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1873475
gptkb:DB09054
11625890
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
infections
hepatotoxicity
inflammatory bowel disease
pneumonitis
|
|
gptkbp:target
|
gptkb:PI3K_delta
|
|
gptkbp:UNII
|
8L2I2MIG2K
|
|
gptkbp:usedFor
|
gptkb:small_lymphocytic_lymphoma
chronic lymphocytic leukemia
follicular lymphoma
|
|
gptkbp:bfsParent
|
gptkb:protein
|
|
gptkbp:bfsLayer
|
4
|